Biofrontera (BFRI) Net Cash Flow Growth (3y) (2023 - 2025)
Biofrontera (BFRI) Net Cash Flow Growth (3y) (2023 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.70 Bn | 30.76 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.73 Bn | 23.67 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.18 Bn | 18.37 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | -62.71% |
| 10 | Biofrontera | 10.88 Mn | 4.47 Mn | 14.09 Mn | 31.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 31.67% |
| Sep 30, 2025 | 4.30% |
| Jun 30, 2025 | -240.88% |
| Mar 31, 2025 | -25.09% |
| Dec 31, 2024 | -48.88% |
| Sep 30, 2024 | -5.78% |
| Jun 30, 2024 | 35.48% |
| Mar 31, 2024 | 39.85% |
| Dec 31, 2023 | -36.99% |